TABLE 1.
Country | Vaccine | Manufacturer | Start of vaccination (yr) | % Coverage | Vaccination schedule | Incidence/100,000a | Protein variant expressed in vaccine
|
|||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Vaccine strain | PtxAf | Prn | FHA | Fim | TcfA | |||||||
Finland | WCVb | KTLc | 1952 | 96 | 3, 4, 5, 24 mo | 6-18 | 1772 | PtxA2 | Prn1 | NDh | Fim2,3 | ND |
18530 | PtxA4 | Prn1 | ND | Fim3 | ND | |||||||
Swedend | ACV | Glaxo-SmithKline | 1996 | ∼100% | 3, 5, 12 mo | 11-31 | Tohama | PtxA2 | Prn1 | ND | NPg | NP |
ACV | Aventis-Pasteur MSD | 1997 | ∼100% | 3, 5, 12 mo | 11-31 | ND | NP | ND | NP | NP | ||
Germany (FRG) | WCV | Behringwerke | 1955-1998 | variable | 3, 4, 5, 12-15 mo | ND | ND | ND | ND | ND | ||
Germany (GDR) | WCV | State Institute | 1964-1989 | >95 | ND | ND | ND | ND | ND | |||
Germany | ACV | Glaxo-SmithKline | 1995 | >95 | 3, 4, 5, 11-14 mo, 9-17 yr, health care personnel | 6-20 | Tohama | PtxA2 | Prn1 | ND | NP | NP |
Aventis-Pasteur MSD | 1995 | >95 | 3, 4, 5, 11-14 mo, 9-17 yr, health care personnel | 6-20 | ND | NP | ND | NP | NP | |||
Chiron-Behring | 1995 | >95 | 3, 4, 5, 11-14 mo, 9-17 yr, health care professional | 6-20 | ND | ND | ND | NP | NP | |||
The Netherlands | WCV | NVIe | 1953 | 96 | 3, 4, 5, 11 mo | 14-44 | 134 | PtxA2 | Prn1 | FhaB1 | Fim3 | TcfA2 |
509 | PtxA4 | Prn7 | FhaB2 | Fim2 or Fim2,3 | TcfA2 | |||||||
France | WCV | Aventis-Pasteur MSD | 1959 | >90 | 2, 3, 4, 16-18 mo (until 1998) | IM1414 | PtxA4 | Prn1 | ND | Fim 2 + 3 | ND | |
IM1416 | PtxA2 | Prn1 | ND | Fim2 | ND | |||||||
ACV | Glaxo-SmithKline | 1998 | 16-18 mo, 11-13 yr | Tohama | PtxA2 | Prn1 | ND | NP | NP | |||
Aventis-Pasteur MSD | 1998 | 16-18 mo, 11-13 yr | ND | NP | ND | NP | NP |
Care should be taken when comparing incidences between countries, because of the different surveillance and diagnostic methods used.
Vaccine contains equal amounts of the two strains.
National Public Health Institute, Helsinki, Finland.
In the Northern part of Sweden mainly a three-component ACV is used; in the southern part, a two-component ACV is used.
Netherlands Vaccine Institute, Bilthoven, The Netherlands.
PtxA, pertussis toxin S1 subunit.
NP, not present.
ND, not determined.